PARP1 degrader-3

PARP1 degrader-3 (compound 7i) (48 h) reduces SW620 cell viability with an IC₅₀ of 5.62 μM^[1].
PARP1 degrader-3 (1.25-20 μM; 24 h) decreases PARP1 protein levels in SW620 cells in a concentration-dependent manner, with a DC₅₀ of 4.31 μM^[1].
PARP1 degrader-3 (5 μM; 3-48 h) induces significant PARP1 degradation in SW620 cells starting at 6 h, with PARP1 protein reduced by more than 80% after 24 h and remaining at low levels up to 48 h^[1].
PARP1 degrader-3 (5 μM; combined with MG132 (HY-13259), PS341 (HY-10227), or Chloroquine (HY-17589A)) induces PARP1 degradation in SW620 cells; MG132 and PS341 markedly attenuate this effect, whereas Chloroquine does not significantly affect PARP1 degradation, supporting its primary dependence on the ubiquitin-proteasome system^[1].
PARP1 degrader-3 (5 μM; combined with HSP70 and/or HSP90 inhibitors) reduces PARP1 protein levels in SW620 cells; inhibition of HSP70 or HSP90 partially restores PARP1, and combined inhibition of both produces a more pronounced restoration effect^[1].
PARP1 degrader-3 (0-3.2 μM; 24 h) decreases PARP1 protein levels in SW480 cells in a concentration-dependent manner^[1].
PARP1 degrader-3 (0-10 μM; 24 h) decreases PARP1 protein levels in HT-29 cells in a concentration-dependent manner^[1].
PARP1 degrader-3 (0-10 μM; 24 h) reduces PARP1 protein levels in HCT116 cells, with a more pronounced effect at 10 μM^[1].
PARP1 degrader-3 (1.25-5 μM; 24 h) induces apoptosis in SW620 cells in a concentration-dependent manner, with the total apoptosis rate increasing from 9.64% in the control group to 22.04%, 42.3%, and 56.9%, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.